WO2015016818A1 - Nouvel agent thérapeutique oral antiviral dérivé d'azolo-1,2,4-triazine - Google Patents

Nouvel agent thérapeutique oral antiviral dérivé d'azolo-1,2,4-triazine Download PDF

Info

Publication number
WO2015016818A1
WO2015016818A1 PCT/US2013/052599 US2013052599W WO2015016818A1 WO 2015016818 A1 WO2015016818 A1 WO 2015016818A1 US 2013052599 W US2013052599 W US 2013052599W WO 2015016818 A1 WO2015016818 A1 WO 2015016818A1
Authority
WO
WIPO (PCT)
Prior art keywords
azolo
novel
oral therapeutic
molecule
triazine derived
Prior art date
Application number
PCT/US2013/052599
Other languages
English (en)
Inventor
Asghar GHIAS
David Evans
Oleg I KISELEV
Original Assignee
Ghias Asghar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ghias Asghar filed Critical Ghias Asghar
Priority to PCT/US2013/052599 priority Critical patent/WO2015016818A1/fr
Publication of WO2015016818A1 publication Critical patent/WO2015016818A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

Definitions

  • the present invention relates to antiviral molecules.
  • the invention relates to an oral therapeutic which uses a TZV molecule which is potent and safe in in vitro assays.
  • Viruses cause periodic pandemics in the human population.
  • the antiviral drugs approved to combat influenza virus infections in particular are currently limited, as are drugs to combat Ebola, Dengue fever, and other infections.
  • the TZV molecule has been shown experimentally to provide some potency against influenza and other viral infections.
  • Fig. 1 shows the molecule of the present invention.
  • diazoazoles 2a*,b* were obtained by treatment of 2-R-amino- 1,2,4-
  • TZV TZV
  • concentration Ec50 the TZV molecule is potent and safe in in vitro assays and can reduce viral replication by 50%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un nouvel agent thérapeutique oral présentant une activité puissante contre des virus de fièvre hémorragique. Une molécule de TZV qui est non toxique, efficace contre de nombreux virus et sûre dans des tests in vitro est produite sous une forme de comprimé ou une autre forme qui peut ingérée oralement. L'agent thérapeutique réduit la réplication virale et la viabilité cellulaire.
PCT/US2013/052599 2013-07-29 2013-07-29 Nouvel agent thérapeutique oral antiviral dérivé d'azolo-1,2,4-triazine WO2015016818A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2013/052599 WO2015016818A1 (fr) 2013-07-29 2013-07-29 Nouvel agent thérapeutique oral antiviral dérivé d'azolo-1,2,4-triazine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/052599 WO2015016818A1 (fr) 2013-07-29 2013-07-29 Nouvel agent thérapeutique oral antiviral dérivé d'azolo-1,2,4-triazine

Publications (1)

Publication Number Publication Date
WO2015016818A1 true WO2015016818A1 (fr) 2015-02-05

Family

ID=52432193

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/052599 WO2015016818A1 (fr) 2013-07-29 2013-07-29 Nouvel agent thérapeutique oral antiviral dérivé d'azolo-1,2,4-triazine

Country Status (1)

Country Link
WO (1) WO2015016818A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3064501A4 (fr) * 2013-11-01 2017-04-12 Limited Liability Company "Ural Center of Biopharmaceutical Technology" 2-méthylsilfanlyl-6-nitr-7-oxo-1,2,4-triazolo[5,1-c][1,2,4]triazinide l-alginine dihydrate ayant une activité contre le virus de la fièvre du nil occidental
WO2017144709A1 (fr) * 2016-02-24 2017-08-31 Doring International Gmbh Médicament antiviral
WO2017144708A3 (fr) * 2016-02-24 2017-11-09 Doring International Gmbh Médicament antiviral
WO2018035509A3 (fr) * 2016-08-19 2018-03-29 Grl, Inc. Petites molécules ayant des propriétés antivirales

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050096320A1 (en) * 1999-12-24 2005-05-05 Bayer Pharmaceuticals Corporation Triazolotriazinones and the use thereof
WO2013122575A2 (fr) * 2012-02-14 2013-08-22 Grl Petite moléculs présentant des propriétés antivirales

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050096320A1 (en) * 1999-12-24 2005-05-05 Bayer Pharmaceuticals Corporation Triazolotriazinones and the use thereof
WO2013122575A2 (fr) * 2012-02-14 2013-08-22 Grl Petite moléculs présentant des propriétés antivirales

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CID 16 June 2011 (2011-06-16), accession no. 2947239 *
KARPENKO ET AL.: "Antiviral Properties, Metabolism, and Pharmacokinetics of a Novel Azolo- 1,2,4-Triazine-Derived Inhibitor of Influenza A and B Virus Replication", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 54, no. 5, May 2010 (2010-05-01), pages 2017 - 2022 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3064501A4 (fr) * 2013-11-01 2017-04-12 Limited Liability Company "Ural Center of Biopharmaceutical Technology" 2-méthylsilfanlyl-6-nitr-7-oxo-1,2,4-triazolo[5,1-c][1,2,4]triazinide l-alginine dihydrate ayant une activité contre le virus de la fièvre du nil occidental
WO2017144709A1 (fr) * 2016-02-24 2017-08-31 Doring International Gmbh Médicament antiviral
WO2017144708A3 (fr) * 2016-02-24 2017-11-09 Doring International Gmbh Médicament antiviral
US11370797B2 (en) 2016-02-24 2022-06-28 Doring International Gmbh Anti-viral drug
WO2018035509A3 (fr) * 2016-08-19 2018-03-29 Grl, Inc. Petites molécules ayant des propriétés antivirales

Similar Documents

Publication Publication Date Title
Sourimant et al. 4′-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication
US20160022724A1 (en) Methods for treating paramyxoviruses
WO2015016818A1 (fr) Nouvel agent thérapeutique oral antiviral dérivé d'azolo-1,2,4-triazine
Kutryb-Zajac et al. Therapeutic perspectives of adenosine deaminase inhibition in cardiovascular diseases
Li et al. Synthesis and biological evaluation of heat-shock protein 90 inhibitors: geldanamycin derivatives with broad antiviral activities
WO2018081449A1 (fr) Méthode pour le traitement d'une infection par le virus respiratoire syncytial
Chupakhin et al. Triazavirin—A novel effective antiviral drug
Oslovsky et al. Fluorination of naturally occurring N 6-benzyladenosine remarkably increased its antiviral activity and selectivity
RU2738719C1 (ru) Средство для лечения коронавирусных, ретровирусных инфекций и гепатита с
Hassanzadeh et al. Characterizing cellular responses during oncolytic maraba virus infection
Sibiya et al. Spirulina platensis ameliorates oxidative stress associated with antiretroviral drugs in hepg2 cells
CN113277994A (zh) 噻唑类化合物及其制备方法和用途
Li et al. Nicotinamide efficiently suppresses porcine epidemic diarrhea virus and porcine deltacoronavirus replication
Falynskova et al. Antiviral activity of fullerene-(tris-aminocaproic acid) hydrate against respiratory syncytial virus in HEp-2 cell culture
RU2536874C1 (ru) 2-МЕТИЛСУЛЬФАНИЛ-6-НИТРО-7-ОКСО-1,2,4-ТРИАЗОЛО[5,1-c] [1,2,4]ТРИАЗИНИД L-АРГИНИНИЯ ДИГИДРАТ, ОБЛАДАЮЩИЙ ПРОТИВОВИРУСНОЙ АКТИВНОСТЬЮ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ЛИХОРАДКИ ЗАПАДНОГО НИЛА
Kobylarz et al. Antidotes in Clinical Toxicology—Critical Review
CN115804775A (zh) S63845在制备抗新冠病毒感染药物中的应用
Rabie Exploration of the potent toxic intracellular effects of the natural adenosine analog cordycepin against SARS-CoV-2 replication
Masood et al. Isoniazid-induced psychosis in a patient on DOTS therapy
WO2018035509A2 (fr) Petites molécules ayant des propriétés antivirales
Beauvais Memory of water and blinding
Gaonkar et al. Favipiravir (6‐Fluoro‐3‐hydroxy‐2‐pyrazinecarboxamide) a Broad Spectrum Inhibitor of Viral RNA Polymerase in COVID‐19 Treatment
EP3300735B1 (fr) Médicament à action hépatoprotectrice
JP2520252B2 (ja) グリチルリチン誘導体
WO2018222774A1 (fr) Méthodes de traitement des pneumovirus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13890348

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13890348

Country of ref document: EP

Kind code of ref document: A1